Pioglitazone in the treatment of acromegaly

The effects on insulin-like growth factor 1 (IGF-1) and growth hormone levels using Pioglitazone in the treatment of active acromegaly

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000780055

Enrollment

Registered

2010-09-20

Start date

2009-06-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To study the effects of pioglitazone (3 months at maximum dose of 45mg) on disease activity of acromegaly, as measured by IGF-1 level.

Interventions

Pioglitazone - 1month run in period of 15mg (2 weeks) and 30mg (2 weeks)orally daily, then target dose of 45mg orally daily for further 3 months

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Active acromegaly - clinical features, elevated IGF-1 and/or non-suppressible growth hormone (>1mcg/L) after 75g oral glucose.

Exclusion criteria

Initiation or discontinuation of octreotide in the last 6 months Initiation or discontinuation of cabergoline in the last 3 months if treatment caused >20% change in serum IGF-1 Congestive heart failure (New York Heart Association (NYHA)Grade 2 or above) Current thiozolidinedione use Current malignancy Clinical liver disease

Outcome results